Insulin was discovered more than 90 years ago and has since been the main therapeutic agent in the management of T1DM; however, in some cases, exogenous insulin replacement is not able to provide the necessary metabolic regulation to prevent primary (hypoglycemic episodes)3 and secondary long-term complications (e.g., vasculopathy, cardiovascular diseases, diabetic nephropathy, neuropathy and retinopathy)4. The gene discussed is INS; the disease is diabetic kidney disease.